We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dependence on Lab Animals for Testing Asthma and Allergy Agents Reduced with 3D Test

By LabMedica International staff writers
Posted on 13 Apr 2014
Print article
In a recent study, scientists report that they’ve developed a simple, three-dimensional (3D) laboratory technique to test asthma and allergy medications that mimics what occurs in the body, which could help reduce the need for animal testing.

Dr. Amir Ghaemmaghami and colleagues from the University of Nottingham (UK) noted that respiratory disorders, such as asthma and allergies, are becoming more common. These conditions affect the lungs and the airway leading to the lungs, making it difficult to breathe. Respiratory symptoms lead to expensive hospital visits, as well as absences from work and school. Improved agents could provide better relief, but before giving new medicines to people, researchers must first test them in animals—an expensive and arduous process. Sometimes, researchers will use 2D tests in which they apply the drug to a layer of human cells in a lab dish instead, but this is not a satisfactory way to tell how a pharmaceutical agent will perform in a whole animal or a whole individual. Therefore, Dr. Ghaemmaghami’s team developed a new, 3D alternative.

Their test includes three types of human cells that are typically in a person’s airway. In the body, these cells are close together and are involved in the development of respiratory conditions. The 3D model reacted similar to an actual person’s airway when they exposed it to allergens and bacterial extract. They say that the model has the potential of reducing the need for some animal testing of new drugs for respiratory conditions.

The study’s findings were published March 14, 2014, in the ACS’ journal Molecular Pharmaceutics.

Related Links:

University of Nottingham


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more